welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Validating Cardiac MRI Biomarkers and Genotype-Phenotype Correlations for DMD
study id #: NCT02834650
condition: Duchenne Muscular Dystrophy
This study will collect MRI from healthy volunteer boys and boys with Duchenne Muscular Dystrophy (DMD) to help researchers identify and validate cardiac MRI biomarkers to better understand the health of the heart and changes in heart health over time in boys with DMD. Currently, there is a lack of sufficiently well characterized cardiac MRI biomarkers that can serve as endpoints for detecting on-target and/or off-target cardiac effects during clinical drug trials for boys with DMD. Consequently, the first objective is to identify and characterize several cardiac MRI biomarkers for boys with DMD.
Cardiac MRI with contrast, Cardiac MRI without contrast, Blood Test, Heart Rate, Pulmonary Function Test, Genetic Testing, Repeat MRI scan
mechanism of action: No pharmaceutical intervention
last updated: February 04, 2020
start date: February 1, 2017
estimated completion: January 2021
phase of development: N/A
size / enrollment: 178
The second objective is to use their well-characterized cardiac MRI biomarkers and define their sensitivity for detecting early cardiac involvement. The final objective is to use these validated cardiac MRI biomarkers to better understand the genotype-phenotype correlation in boys with DMD, which to date remain tenuous. The investigators propose a pilot study to explore cardiac genotype-phenotype correlations in boys with DMD and outlier phenotypes using approaches they have pioneered for skeletal muscle.
- Myocardial Tissue Characterization [ Time Frame: 6 months ]
Focal and diffuse fibrosis, intra myocardial fat, edema plus water mobility
- Myocardial Functional Characterization [ Time Frame: 6 months ]
Strain imaging and rotational mechanics
- Genomic Analysis [ Time Frame: 4 years ]
Proposing mechanisms of cardiac dysfunction or protective phenotypes using genomic analysis
• Eligible Sexes: male
• Healthy boys or pediatric patients with DMD age 7 to 21
• Able & willing to complete an approximately 75-minute (or less) MRI exam without sedation or mechanical ventilation
• Drug regimen (if applicable) stable for at least 3 months prior to participation
• Renal insufficiency (GFR<40 mL/min/m2)
• Non-MRI compatible implants (e.g. neurostimulator, pacemaker, implanted cardioverter defibrillator)
• Claustrophobia that prevents an MRI exam
• Known allergy to MRI contrast agents
• Serum potassium level of >5.0 mmol/L
• Signs and symptoms of heart failure
An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability DeflazacortThis is an open label, long-term extensi...
Magnetic Resonance and Optical Imaging of Dystrophic and Damaged MuscleThe purpose of this research study is to...
A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD)The purpose of this study is to determin...
Edasalonexent could reduce functional decline in boys with DMD, MoveDMD phase 2 results suggestResults of the Phase 2 MoveDMD trial sho...
A Study of Tadalafil for Duchenne Muscular DystrophyThe main purpose of this study is to det...
Observational Study of Patients With Duchenne Muscular Dystrophy Theoretically Treatable With Exon 53 SkippingPreU7-53 is a natural history study. The...
A 2-Part Study to Assess the Safety and Tolerability, pk, Effects on Histology and Some Clinical Parameters of Givin...This is a 2-part, phase 2 study to asses...
Clinical trial of gene therapy for Duchenne muscular dystrophy underway at University of Florida HealthScreening has resumed in a clinical tria...
Extracellular RNAs in Urine May Work as Biomarker for Duchenne and Myotonic Dystrophy PatientsExtracellular RNAs found in urine may be...
First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular DystrophyAntisense Therapeutics today announced d...
Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy ProgramSarepta Therapeutics, Inc., the leader i...